$WVVI

Willamette Valley Vineyards Posts Results for Q2 2026

Willamette Valley Vineyards (NASDAQ: WVVI) reported Q2 2026 results. Loss per common share after preferred dividends was $0.40 versus $0.09 in Q2 2025. Sales were $10.04M, down 1.6% year over year. Gross profit fell to $5.77M. Net loss was $1.39M versus net income of $92.8K, citing distributor Republic National Distributing’s bankruptcy.

Original reporting
Published Aug 13, 2026, 2:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Willamette Valley Vineyards Posts Results for Q2 2026 — source image
Decision brief

The 30-second read

$WVVIBearishMed
01

Why it matters

The quarter shows lower revenue and gross profit alongside a sharp SG&A increase, culminating in a larger net loss. The explicit linkage to Republic National Distributing Company’s bankruptcy makes credit risk a key variable for forward estimates.

02

Market read

Traders can update near-term expectations for WVVI’s margins, cash-flow risk, and credit exposure following the Q2 print and its stated bankruptcy-related driver.

03

What to watch

The release notes per-customer spending rose and retail visitations declined less than expected, so demand at the tasting-room level may be more resilient than the headline revenue decline suggests.

Relevance 8/10Novelty 7/10Timing: post-market release of Q2 2026 results (Aug. 12, 2026)

Background

Willamette Valley Vineyards posted Q2 2026 financial results and attributed deterioration largely to a distributor’s bankruptcy and related credit-loss allowances.

Company-level read

Ticker impact

$WVVIBearishMedium confidence
Context

Willamette Valley Vineyards reported Q2 2026 revenue down 1.6% and a net loss of $1.39M, citing distributor Republic National’s bankruptcy.

Expected impact

Likely bearish bias for the next few sessions as traders reprice credit exposure to the bankrupt distributor and the earnings trajectory.

Evidence & confidence

The article discloses concrete quarterly P&L changes (revenue, gross profit, SG&A, net loss) and a specific driver (allowance for credit losses tied to the distributor’s bankruptcy), which can affect expectations for subsequent quarters.

Market effects

Highlights credit and distributor concentration risk for small-cap wine producers, potentially pressuring sentiment across similarly exposed branded beverage names.

Limited, mostly impacts Oregon-based branded wine sentiment rather than broader regional macro.

Low, company-specific credit-loss and sales mix issue with minimal direct global spillover.

Counterpoint

Management frames the quarter as largely driven by one distributor’s bankruptcy, implying results could normalize if credit exposure is contained and new distributors ramp.

Key entities

  • Willamette Valley Vineyards, Inc.

    NASDAQ-listed Oregon Pinot Noir producer reporting Q2 2026 results.

  • Republic National Distributing Company

    Distributor whose bankruptcy triggered an increase in the company’s allowance for credit losses.

  • Jim Bernau

    Founder and President commenting on the distributor-driven cash flow impact and distributor training efforts.

Related articles

$CRWVMedAI 8/10

CoreWeave Has $104 Billion of Contracted Revenue and a $59 Billion Market Value

CoreWeave (NASDAQ: CRWV) reported Q2 results after the close. The company said its revenue backlog was about $104 billion as of June 30, up from $30.1 billion a year earlier. Q2 revenue rose 112% to $2.6 billion. Management guided 2026 revenue to $12.4 billion to $13.2 billion and raised 2026 capex to $35 billion to $39 billion. Shares rose about 19%.

$ICUMed

SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript

SeaStar Medical Holding Corp (ICU) reported Q2 2026 net revenue of $615,000, up 82% year over year, and six-month net revenue of $1.1 million. Gross margin was 91%. Net loss was $3.7 million ($0.91/share). Cash was $7.0 million at June 30, 2026. QUELIMMUNE adoption reached 20 hospitals; NEUTRALIZE-AKI enrolled 223/339 patients.

$WYFIMedAI 8/10

WhiteFiber (WYFI) Q2 2026 Earnings Call Transcript

WhiteFiber (WYFI) reported Q2 2026 revenue of $28.8M, up 54%, driven by cloud services ($23.8M vs $16.6M) and new colocation at MTL 3 ($4.7M). Gross profit was $17.1M (59% margin). Net loss was $15M ($0.39/share); adjusted EBITDA $5.5M. Management cited $865M 10-year NC1 contract and financing progress.

$ECXMedAI 8/10

ECARX shares rise as Q2 revenue jumps 45% and losses narrow

ECARX Holdings Inc. (NASDAQ:ECX) shares rose premarket after Q2 results. For quarter ended June 30, revenue increased 45% YoY to $225.2M. Net loss narrowed to $12.0M, or -$0.03 per share. Gross margin rose to 19.8% and adjusted EBITDA turned positive at $0.5M. Company kept 2026 revenue guidance at $1.0B-$1.1B but warned memory costs may pressure margins.

$ALCMedAI 8/10

Tariff refund boosts Alcon’s second quarter results

Alcon (NYSE: ALC) reported 2Q 2026 net sales of $2.8B, up 8% year over year, and raised its 2026 outlook. The company expects a $60M U.S. tariff refund after cutting its estimated tariff burden to $40M, and plans to reinvest about two-thirds. Operating income fell to $11M due to a $402M pre-tax charge from discontinuing PowerVision IOL programs. It returned $469M to shareholders.